The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Common Misconceptions Clarified: Ankylosing Spondylitis & Non-Radiographic Axial Spondyloarthritis

Common Misconceptions Clarified: Ankylosing Spondylitis & Non-Radiographic Axial Spondyloarthritis

March 23, 2022 • By Jason Liebowitz, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

With respect to MRI, Dr. Deodhar pointed out that bone marrow edema at the sacroiliac joints can be seen in many healthy individuals and should not be used to diagnose spondyloarthritis without taking into account the entire clinical picture.

You Might Also Like
  • New Guideline: NSAIDs Effective in Treating Ankylosing Spondylitis & Nonradiographic Axial Spondyloarthritis
  • Ixekizumab Improves Outcomes of Ankylosing Spondylitis
  • FDA Approves Secukinumab for Non-Radiographic Axial Spondyloarthritis
Explore This Issue
April 2022
Also By This Author
  • Clinical Pearls: What We Know About Nonradiographic Axial Spondyloarthritis

Weber et al. conducted a study in which MRI scans (T1‐weighted and short tau inversion recovery [STIR] sequences) of the sacroiliac joints were obtained from 187 subjects, including patients with non-specific back pain and healthy controls.3 Bone marrow edema, erosions and fat infiltration were observed in up to 27% of control subjects with non-specific back pain and in 24% of health controls.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Although it is possible that some of these patients may have clinically asymptomatic, atypical or early spondyloarthritis, the authors point out that the presence of low-grade, acute lesions of the sacroiliac joints may be due to mechanically induced signal alterations or degenerative changes, and, thus, care should be taken not to misclassify some young patients with back pain as having spondyloarthritis. The authors note that erosions were much less frequently observed in both control groups when compared with bone marrow edema and fat infiltration. Thus, erosive findings may be more specific for true spondyloarthritis.3

Treatment Recommendations

Dr. Deodhar also discussed the 2019 update of the ACR/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nr-axSpA.4 He noted that, in these guidelines, treatment recommendations for ankylosing spondylitis and nr-axSpA are similar.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Tumor necrosis factor (TNF) inhibitors remain recommended as the first-line biologic treatment for these patients and are recommended over interleukin-17 (IL-17) inhibitors, mostly because a more robust response is achieved using TNF inhibitor treatment and because TNF inhibitors treat many of the extra-articular manifestations of disease, such as uveitis. However, in patients who have had a primary nonresponse to TNF inhibitors, IL-17 inhibitors are recommended over trying a second TNF inhibitor.

TNF and IL-17 inhibitors are both recommended over using tofacitinib in patients with ankylosing spondylitis and nr-axSpA. Sulfasalazine was included in the guidelines as a treatment only for persistent peripheral arthritis and not for treatment of axial involvement.

Although routine monitoring of C-reactive protein is indicated for all patients, this is not the case for routine monitoring with MRI or radiographs of the spine or sacroiliac joints.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

In addition, screening for osteoporosis with bone density scans is recommended for these patients.

Regarding items that are not advisable, the authors state that co-administration of low-dose methotrexate with a TNF inhibitor is not recommended. Discontinuation or tapering of biologics in patients with stable disease is also not recommended.4

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports, Spondyloarthritis Tagged With: Advances in the Diagnosis and Treatment of the Rheumatic Diseases meeting, Ankylosing Spondylitis, AS Resource Center, non-radiographic axial spondyloarthritis, spondyloarthritisIssue: April 2022

You Might Also Like:
  • New Guideline: NSAIDs Effective in Treating Ankylosing Spondylitis & Nonradiographic Axial Spondyloarthritis
  • Ixekizumab Improves Outcomes of Ankylosing Spondylitis
  • FDA Approves Secukinumab for Non-Radiographic Axial Spondyloarthritis
  • Adalimumab May Help Maintain Remission in Non-Radiographic Axial Spondyloarthritis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)